These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32049796)

  • 1. Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study.
    Chérin P; Pindi Sala T; Clerson P; Dokhan A; Fardini Y; Duracinsky M; Crave JC; Chassany O
    Medicine (Baltimore); 2020 Feb; 99(7):e19012. PubMed ID: 32049796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.
    Danieli MG; Verga JU; Mezzanotte C; Terrenato I; Svegliati S; Bilo MB; Moroncini G
    Front Immunol; 2021; 12():805705. PubMed ID: 35111165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis.
    Danieli MG; Moretti R; Gambini S; Paolini L; Gabrielli A
    Clin Rheumatol; 2014 Apr; 33(4):531-6. PubMed ID: 24395197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application.
    Danieli MG; Pettinari L; Moretti R; Logullo F; Gabrielli A
    Autoimmun Rev; 2011 Jan; 10(3):144-9. PubMed ID: 20858553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.
    Wang DX; Shu XM; Tian XL; Chen F; Zu N; Ma L; Wang GC
    Clin Rheumatol; 2012 May; 31(5):801-6. PubMed ID: 22274797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients.
    Marie I; Menard JF; Hatron PY; Hachulla E; Mouthon L; Tiev K; Ducrotte P; Cherin P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1748-55. PubMed ID: 20722047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.
    Cherin P; Belizna C; Cartry O; Lascu-Dubos G; de Jaeger C; Delain JC; Crave JC; Hachulla E
    Autoimmun Rev; 2016 Mar; 15(3):281-6. PubMed ID: 26688441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
    Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
    Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
    Cinetto F; Neri R; Vianello F; Visentin A; Barilà G; Gianese S; Lanciarotta A; Milito C; Rattazzi M; Piazza F; Trentin L; Zambello R; Agostini C; Scarpa R
    PLoS One; 2021; 16(3):e0247717. PubMed ID: 33661940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience.
    Ma Z; Johnson D; Gniadecki R; Ritchie B; Keeling S; Cohen Tervaert JW; Osman M
    Rheumatology (Oxford); 2024 Aug; 63(8):2118-2122. PubMed ID: 37796840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of intravenous immunoglobulins in polymyositis and dermatomyositis. An open trial in 15 patients].
    Cherin P; Herson S; Wechsler B; Piette JC; Bletry O; Degennes C; Ziza JM; Du LT; Godeau P
    Presse Med; 1991 Feb; 20(6):244-9. PubMed ID: 1706860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current therapy for polymyositis and dermatomyositis].
    Chérin P
    Rev Med Interne; 2008 Jun; 29 Spec No 2():9-14. PubMed ID: 18927983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
    Martin A; Lavoie L; Goetghebeur M; Schellenberg R
    Transfus Med; 2013 Feb; 23(1):55-60. PubMed ID: 23167310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis.
    Patrick C; Jean-Christophe D; Jean-Charles C; Odile C
    Case Rep Rheumatol; 2014; 2014():458231. PubMed ID: 25140268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a Personalized Subcutaneous Immunoglobulin Treatment Program for Neurological Patients.
    Suleman A; Theoret L; Bourque P; Pringle E; Cameron DW; Cowan J
    Can J Neurol Sci; 2019 Jan; 46(1):38-43. PubMed ID: 30688201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
    Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
    Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.
    Cherin P; Herson S; Wechsler B; Piette JC; Bletry O; Coutellier A; Ziza JM; Godeau P
    Am J Med; 1991 Aug; 91(2):162-8. PubMed ID: 1714235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.